Lopanov-SR75 Tablet contains Levosulpiride 75 mg as its active ingredient and is primarily indicated for the treatment of functional dyspepsia, gastroesophageal reflux disease (GERD), and other gastrointestinal motility disorders. Levosulpiride is a selective dopamine D2 receptor antagonist with prokinetic and antiemetic properties, which facilitates gastric emptying and improves gastrointestinal motility without affecting gastric acid secretion. It is also utilized in the management of symptoms related to delayed gastric emptying such as nausea, vomiting, bloating, and abdominal discomfort. Additionally, Levosulpiride exhibits central nervous system activity and is sometimes prescribed for psychiatric conditions including depression and schizophrenia, although this formulation is specifically targeted for gastrointestinal use. Lopanov-SR75 is formulated as a sustained-release tablet to provide prolonged therapeutic effects and improve patient compliance by reducing dosing frequency. The medication should be used under medical supervision, with caution advised in patients with prolactin-dependent tumors, renal or hepatic impairment, and those with a history of extrapyramidal symptoms. Common adverse effects may include drowsiness, dizziness, and mild gastrointestinal disturbances. It is contraindicated in patients with hypersensitivity to Levosulpiride or related compounds. Proper adherence to prescribed dosage and monitoring is essential to ensure efficacy and minimize potential side effects.